Cargando…
Gene Editing with CRISPR/Cas Methodology and Thyroid Cancer: Where Are We?
SIMPLE SUMMARY: The advent of genomic editing with CRISPR/Cas9 has transformed the way we manipulate the genome, and has facilitated the investigation of tumor cell biology in vitro and in vivo. Not only we can modify genome sequence to blunt an overactivated gene or correct a mutation, but also we...
Autores principales: | Fuziwara, Cesar Seigi, de Mello, Diego Claro, Kimura, Edna Teruko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834610/ https://www.ncbi.nlm.nih.gov/pubmed/35159110 http://dx.doi.org/10.3390/cancers14030844 |
Ejemplares similares
-
Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer
por: de Santa-Inez, Daniel Casartelli, et al.
Publicado: (2021) -
MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology
por: Fuziwara, Cesar Seigi, et al.
Publicado: (2014) -
Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer
por: de Mello, Diego Claro, et al.
Publicado: (2023) -
How does microRNA modulate Wnt/β-catenin signaling in thyroid oncogenesis?
por: Fuziwara, Cesar Seigi, et al.
Publicado: (2020) -
Interplay of TGFβ signaling and microRNA in thyroid cell loss of differentiation and cancer progression
por: Fuziwara, Cesar Seigi, et al.
Publicado: (2019)